Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
MetFlex is an investigator led, open-label, single-arm, Phase 2a trial to determine the
safety and tolerability of trimetazidine for the treatment of amyotrophic lateral
sclerosis/motor neuron disease (ALS/MND).
Phase:
Phase 2
Details
Lead Sponsor:
The University of Queensland
Collaborators:
FightMND Julius Clinical, The Netherlands King's College London UMC Utrecht